Published Manuscripts (2016)

Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS ONE 2016; 11(11): e0160421.

Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine W. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. ClinicoEconomics and Outcomes Research 2016; 8: 559-71.

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer BF, Reznik Y, de Valk HW. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. Journal of Medical Economics 2016; 19(8): 742-9

Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics 2016; 19(7): 672-83.

Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of Medical Economics 2016; 19(10): 995-1002.

Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, de Portu S, Pickup JC. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. Journal of Medical Economics 2016; 19(3): 236-4.

Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics 2016; 19(2): 121-34.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients. Advances in Therapy 2016; 33(3): 345-56.

Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technology & Therapeutics 2016; 18(2): 75-84.

Muduma G, Odeyemi I, Pollock RF. Evaluating the cost-effectiveness of prolonged-release tacrolimus relative to immediate-release tacrolimus in liver transplant patients based on data from routine clinical practice. Drugs Real World Outcomes 2016; 3: 61-8.